Daily Newsletter

18 October 2023

Daily Newsletter

18 October 2023

Covenant and UCG launch Tennessee urgent care centre

This collaboration claims to offer fast, friendly, and affordable healthcare services in East Tennessee.

October 18 2023

Covenant Health and Urgent Care Group (UCG) have joined forces to launch the first Covenant Health Urgent Care (CHUC) in South Knoxville, Tennessee, US.

This collaboration claims to offer fast, friendly, and affordable healthcare services in East Tennessee, with plans for further expansion.

Located in Covenant Health South, the 47,346ft² facility provides care from 8am to 8pm, seven days a week.

It features X-ray imaging, lab services, occupational health, Covid-19 testing, and injury care.

This new medical facility also aims to provide comprehensive healthcare services, including primary care, cardiology, women's health, imaging, rehabilitation, and more.

Covenant Health president and CEO Jim VanderSteeg said: “This partnership will increase access to medical care in the South Knoxville and Seymour area.

“Urgent care clinics offer a convenient way to receive immediate care for non-life-threatening medical issues, even after traditional office hours and on weekends.

“As a trusted, valued healthcare partner, we hope the opening of this urgent care clinic will improve the overall health of the community.”

The expanded UCG network now includes 57 centres under various brands across multiple states.

UCG CEO David Maloney said: “We are pleased to partner with Covenant Health to provide convenient and affordable urgent care services to East Tennessee, seven days per week.

“We look forward to expanding urgent care services with Covenant Health throughout Knoxville and East Tennessee.”

Covenant Health is a not-for-profit health system dedicated to delivering patient-centred care, while UCG's mission is to provide accessible quality healthcare in communities through partnerships with health systems.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close